Clinical Study
Trimethoprim Use prior to Pregnancy and the Risk of Congenital Malformation: A Register-Based Nationwide Cohort Study
Table 2
Risk of congenital malformations associated with trimethoprim use during the 12-week period prior to conception.
| Reference group | All unexposed children born 1997–2004 | All unexposed children born 1997–2004 adjusteda | Children born 1997–2004 by mothers with one or more prescription of mecillinam prior to pregnancy | Children born 1997–2004 by mothers with no usage of prescription drugs prior to and during pregnancy | | | | |
| Major congenital malformations or (CI 95%) | 1.91 (1.28–2.87) | 1.87 (1.25–2.80) | 1.78 (1.15–2.77) | 2.05 (1.37–3.08) | All congenital malformations or (CI 95%) | 2.01 (1.45–2.78) | 1.96 (1.41–2.72) | 1.90 (1.33–2.72) | 2.18 (1.57–3.03) |
|
|
aAdjusted for age, parity, usage of X-classified drugs, teratogenic infections, folate deficiency, myasthenia gravis, diabetes mellitus, alcoholism, amniocentesis, Sjogren’s syndrome, virilizing tumors, education, and income.
|